Ultragenyx Pharmaceutical Inc. (RARE) News

Ultragenyx Pharmaceutical Inc. (RARE): $36.99

-0.29 (-0.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RARE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 383

in industry

Filter RARE News Items

RARE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RARE News Highlights

  • RARE's 30 day story count now stands at 2.
  • Over the past 14 days, the trend for RARE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest RARE News From Around the Web

Below are the latest news stories about ULTRAGENYX PHARMACEUTICAL INC that investors may wish to consider to help them evaluate RARE as an investment opportunity.

Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

Dr. Camille Bedrosian to continue employment as strategic development advisor with the company Eric Crombez, M.D. Eric Crombez, M.D. NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role. Dr. Crombez currently serves as

Yahoo | March 14, 2023

Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference

NOVATO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will participate in an Orphan Neuro Panel at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 10:30 a.m. ET. The live and archived

Yahoo | February 28, 2023

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2022 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2022 Earnings Call Transcript February 16, 2023 Operator: Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2022 Financial Results Conference Call. It is now my pleasure to turn the call over to Joshua Higa, Executive Director and Head of Investor Relations. Joshua Higa: Thank you. We […]

Yahoo | February 20, 2023

12 Stocks To Sell According to Motley Fool

In this article, we will be looking at 12 stocks to sell according to Motley Fool. To skip our detailed analysis of current market dynamics heading into 2023, you can go directly to see the 5 Stocks To Sell According to Motley Fool. Motley Fool Asset Management focuses on high-quality growth companies, and it is constantly […]

Yahoo | February 19, 2023

Ultragenyx Pharmaceutical Full Year 2022 Earnings: In Line With Expectations

Ultragenyx Pharmaceutical ( NASDAQ:RARE ) Full Year 2022 Results Key Financial Results Revenue: US$363.3m (up 3.4% from...

Yahoo | February 19, 2023

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

In this article we are going to estimate the intrinsic value of Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) by...

Yahoo | February 18, 2023

Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y

Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.

Yahoo | February 17, 2023

Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita® revenue of $279.4 million and Dojolvi® revenue of $55.6 million 2023 expected Total Revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million Year-end 2022 cash balance of $896.7 million and 2023 guidance for Net Cash used in Operations expected to be less than $400 million NOVATO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Ultr

Yahoo | February 16, 2023

Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others

Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.

Yahoo | February 15, 2023

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update

NOVATO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, February 16, 2023, at 5:00 p.m. ET to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2022. The live and replayed webcast of the call

Yahoo | February 9, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.674 seconds.